Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses RGEN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RGEN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Olivier Loeillot | $860,000 | $0 | $3,374,853 | $1,095,626 | $774,000 | $0 | $10,292 | $6,114,771 |
| President and Chief Executive Officer | ||||||||
| Jason Garland | 566,500 | 0 | 1,499,727 | 486,909 | 430,186 | 0 | 5,000 | 2,988,322 |
| Chief Financial Officer | ||||||||
| James Bylund | 481,197 | 0 | 1,589,562 | 486,909 | 365,409 | 0 | 9,442 | 2,932,519 |
| Chief Operating Officer | ||||||||
| Ralf Kuriyel | 420,548 | 0 | 1,214,631 | 365,182 | 319,354 | 0 | 9,206 | 2,328,921 |
| Senior Vice President, Research and Development | ||||||||
| Brian Douglass | 417,150 | 0 | 912,284 | 184,404 | 212,747 | 0 | 8,209 | 1,734,794 |
| Senior Vice President, Chief Product Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Olivier Loeillot | $6,114,771 | $7,184,359 | $5,445,065 | −1,069,588 |
| Jason Garland | 2,988,322 | 2,107,416 | 2,026,471 | +880,906 |
| James Bylund | 2,932,519 | 4,170,772 | 3,743,430 | −1,238,253 |
| Ralf Kuriyel | 2,328,921 | 1,994,138 | 1,661,482 | +334,783 |
| Brian Douglass | 1,734,794 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Olivier Loeillot | Director | 2026-04-21 | D | 3,832 | $140 | $536,480 | Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2026-05-07 | A | 2,434 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Douglass | CHIEF PRODUCT OFFICER | 2026-05-07 | D | 334 | 126 | 42,228 | Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2026-05-07 | A | 2,434 | 39 | 94,342 | Common | Form 4 ↗ |
| Karen A. Dawes | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Rohin Mhatre | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Manner Carrie Eglinton | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Nicolas M. Barthelemy | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Rohin Mhatre | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Margaret A. Pax | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Margaret A. Pax | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Konstantin Konstantinov | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nicolas M. Barthelemy | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Manner Carrie Eglinton | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Konstantin Konstantinov | Director | 2026-05-14 | A | 995 | 0 | 0 | Common | Form 4 ↗ |
| Karen A. Dawes | Director | 2026-05-14 | A | 2,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Garland | CFO | 2026-06-25 | D | 733 | 145 | 106,285 | Common | Form 4 ↗ |
| Jason Garland | CFO | 2026-07-16 | D | 530 | 150 | 79,500 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ralf Kuriyel | PSU | 2025-01-01 | 314 | 628 | — | 1,256 | $89,835 |
| Brian Douglass | OPTION | 2025-12-31 | — | — | 2,143 | — | 184,404 |
| Brian Douglass | RSU | 2025-03-01 | — | — | 2,252 | — | 349,916 |
| Ralf Kuriyel | OPTION | 2025-03-01 | — | — | 4,542 | — | 365,182 |
| Ralf Kuriyel | RSU | 2025-03-01 | — | — | 4,826 | — | 749,864 |
| Jason Garland | OPTION | 2025-03-01 | — | — | 6,056 | — | 486,909 |
| James Bylund | OPTION | 2025-03-01 | — | — | 6,056 | — | 486,909 |
| Brian Douglass | PSU | 2025-12-31 | 572 | 1,144 | — | 2,288 | 187,456 |
| Jason Garland | PSU | 2025-03-01 | 1,609 | 3,217 | — | 6,434 | 499,857 |
| Ralf Kuriyel | PSU | 2025-03-01 | 1,207 | 2,413 | — | 4,826 | 374,932 |
| James Bylund | PSU | 2025-03-01 | 1,609 | 3,217 | — | 6,434 | 499,857 |
| James Bylund | PSU | 2025-01-01 | 314 | 628 | — | 1,256 | 89,835 |
| James Bylund | RSU | 2025-03-01 | — | — | 6,435 | — | 999,870 |
| Jason Garland | RSU | 2025-03-01 | — | — | 6,435 | — | 999,870 |
| Brian Douglass | RSU | 2025-12-31 | — | — | 2,288 | — | 374,912 |
| Olivier Loeillot | PSU | 2025-03-01 | 3,620 | 7,240 | — | 14,480 | 1,124,951 |
| Olivier Loeillot | OPTION | 2025-03-01 | — | — | 13,627 | — | 1,095,626 |
| Olivier Loeillot | RSU | 2025-03-01 | — | — | 14,480 | — | 2,249,902 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ralf Kuriyel | $749,864 | $464,767 | $365,182 | 29.4% |
| Brian Douglass | 724,828 | 187,456 | 184,404 | 17.1% |
| Jason Garland | 999,870 | 499,857 | 486,909 | 25.2% |
| James Bylund | 999,870 | 589,692 | 486,909 | 28.4% |
| Olivier Loeillot | 2,249,902 | 1,124,951 | 1,095,626 | 25.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ralf Kuriyel | PSU | 1,760 | — | $288,394 |
| Jason Garland | RSU | 1,694 | — | 277,579 |
| James Bylund | PSU | 250 | — | 40,965 |
| Ralf Kuriyel | RSU | 4,826 | — | 790,788 |
| Olivier Loeillot | PSU | 8,815 | — | 1,444,426 |
| James Bylund | RSU | 2,783 | — | 456,022 |
| Olivier Loeillot | PSU | 7,240 | — | 1,186,346 |
| James Bylund | PSU | 4,346 | — | 712,136 |
| James Bylund | Option | 2,882 | 180.48 | — |
| Jason Garland | Option | 6,315 | 158.99 | — |
| Ralf Kuriyel | RSU | 1,156 | — | 189,422 |
| Ralf Kuriyel | RSU | 2,347 | — | 384,579 |
| James Bylund | PSU | 2,087 | — | 341,976 |
| James Bylund | PSU | 314 | — | 51,452 |
| Olivier Loeillot | Option | 10,852 | 141.79 | — |
| James Bylund | PSU | 3,217 | — | 527,138 |
| Olivier Loeillot | Option | 14,542 | 154.96 | — |
| Brian Douglass | RSU | 4,000 | — | 655,440 |
| James Bylund | Option | 6,056 | 155.38 | — |
| Olivier Loeillot | RSU | 11,754 | — | 1,926,010 |
| Olivier Loeillot | RSU | 14,480 | — | 2,372,693 |
| James Bylund | RSU | 6,435 | — | 1,054,439 |
| Ralf Kuriyel | PSU | 2,413 | — | 395,394 |
| Brian Douglass | RSU | 2,252 | — | 369,013 |
| Jason Garland | PSU | 3,217 | — | 527,138 |
| Olivier Loeillot | RSU | 1,920 | — | 314,611 |
| Brian Douglass | PSU | 1,144 | — | 187,456 |
| James Bylund | Option | 5,755 | 192.71 | — |
| Jason Garland | RSU | 3,302 | — | 541,066 |
| Brian Douglass | RSU | 2,288 | — | 374,912 |
| Ralf Kuriyel | PSU | 867 | — | 142,067 |
| Jason Garland | Option | 6,056 | 155.38 | — |
| Ralf Kuriyel | Option | 2,332 | 192.71 | — |
| Olivier Loeillot | RSU | 7,744 | — | 1,268,932 |
| Ralf Kuriyel | PSU | 314 | — | 51,452 |
| Brian Douglass | Option | 2,143 | 163.86 | — |
| James Bylund | RSU | 5,794 | — | 949,405 |
| Brian Douglass | Option | 8,000 | 167.72 | — |
| Olivier Loeillot | Option | 1,907 | 192.71 | — |
| Olivier Loeillot | Option | 13,627 | 155.38 | — |
| Ralf Kuriyel | Option | 1,197 | 180.48 | — |
| Ralf Kuriyel | Option | 4,542 | 155.38 | — |
| Jason Garland | Option | 1,682 | 192.71 | — |
| Jason Garland | PSU | 1,270 | — | 208,102 |
| Jason Garland | RSU | 6,435 | — | 1,054,439 |
| Olivier Loeillot | PSU | 1,440 | — | 235,958 |
In accordance with the Company s compensation philosophy, the Company provides compensation that the Compensation Committee believes will attract and retain high-performing talent in our industry, motivate the Company s executive officers to create long-term, enhanced shareholder value and provide a fair reward for robust effort.
| CEO STI target (% of salary) | 90% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Meridian Compensation Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 50,333,558 | 1,513,515 | 51,173 | 96.99% | Passed |
| 2025 | 2025-05-15 | 49,435,575 | 1,720,490 | 44,354 | 96.55% | Passed |
| 2024 | 2024-05-16 | 46,636,342 | 2,832,814 | 66,253 | 94.15% | Passed |
| 2023 | 2023-05-18 | 48,195,853 | 1,375,453 | 40,034 | 97.15% | Passed |
| 2022 | 2022-05-26 | 47,079,986 | 1,160,797 | 49,110 | 97.49% | Passed |
| 2021 | 2021-05-13 | 44,729,097 | 923,077 | 54,383 | 97.86% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-14 | 96.99%a |
| 2025 | 2025-05-15 | 96.55%b |
| 2024 | 2024-05-16 | 94.15%c |
a. Approved under the standard stated in the filing — “Abstentions shall be included in determining the number of shares present and entitled to vote on the proposal, thus having the effect of a vote against the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker "non-votes" will have the same effect as if you voted against such proposal.”.
c. Approved under the standard stated in the filing — “Abstentions shall be included in determining the number of shares present and entitled to vote on the proposal, thus having the effect of a vote against the proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 82 : 1 |
|---|---|
| CEO total compensation | $6,114,771 |
| Median employee compensation | $74,954 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Tony J. HuntEmployee director · Departed during FY | — | — | — | — | $671,000 | $671,000 |
| Karen A. DawesIndependent · Lead Independent Director · Audit | 120,000 | 119,932 | 115,343 | 0 | — | 355,275 |
| Glenn P. MuirIndependent · Audit · Compensation | 105,000 | 119,932 | 115,343 | 0 | — | 340,275 |
| Margaret A. PaxIndependent · Compensation · Nominating and Corporate Governance | 83,528 | 119,932 | 115,343 | 0 | — | 318,803 |
| Martin MadausIndependent · Board Chair · Nominating and Corporate Governance | 81,000 | 119,932 | 115,343 | 0 | — | 316,275 |
| Nicolas M. BarthelemyIndependent · Compensation | 76,472 | 119,932 | 115,343 | 0 | — | 311,747 |
| Rohin MhatreIndependent · Compensation | 70,000 | 119,932 | 115,343 | 0 | — | 305,275 |
| Carrie Eglinton MannerIndependent · Audit | 70,000 | 119,932 | 115,343 | 0 | — | 305,275 |
| Konstantin KonstantinovIndependent · Nominating and Corporate Governance | 65,000 | 119,932 | 115,343 | 0 | — | 300,275 |
| Olivier LoeillotEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $235,275 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 20,000 / 16,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $671,000 |
| Equity awards (grant-date value) | $959,456 |
| All other compensation | $671,000 |
| Total cost of the board | $2,301,456 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Repligen Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Repligen Corp.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Therapeutics, Inc | 2025 | Helen Torley | $1,000,000 | $19,350,145 | $1,650,014 | $1,147,500 | $23,166,223 |
| 2 | Insulet Corporation | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 3 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 4 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 5 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 6 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 7 | Maravai LifeSciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 8 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 9 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 10 | Neogen Corporation | 2025 | John Adent | 810,000 | 1,800,000 | 4,200,000 | 0 | 6,824,891 |
| 11 | Mesa Laboratories, Inc. | 2026 | Gary Owens | 808,846 | 4,700,017 | 0 | 1,120,000 | 6,643,208 |
| 12 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 13 | Repligen Corp | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 14 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 15 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Repligen Corp | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Azenta, Inc. | 107.4% | PSU 50 · RSU 50 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon Talent |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Halozyme Therapeutics, Inc | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Maravai LifeSciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Mesa Laboratories, Inc. | 125% | PSU 50 · RSU 50 | No | Frederic W. Cook & Co, Inc. |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Neogen Corporation | not disclosed | PSU 50 · Option 50 | not disclosed | Farient Advisors, LLC |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Olivier Loeillot | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Executive Compensation Tables” · page 38. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 2 | Section 01, Jason Garland | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Executive Compensation Tables” · page 38. As printed: 2,988,322. Filing ↗machine: t16 · r6 · c2 · span 580048–580057 |
| 3 | Section 01, James Bylund | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Executive Compensation Tables” · page 38. As printed: 2,932,519. Filing ↗machine: t16 · r8 · c2 · span 583025–583034 |
| 4 | Section 01, Ralf Kuriyel | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Executive Compensation Tables” · page 38. As printed: 2,328,921. Filing ↗machine: t16 · r10 · c2 · span 586026–586035 |
| 5 | Section 01, Brian Douglass | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Executive Compensation Tables” · page 38. As printed: 1,734,794. Filing ↗machine: t16 · r12 · c2 · span 589389–589398 |
| 6 | Section 03, Ralf Kuriyel PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r17 · c22 · span 1820768–1820774 |
| 7 | Section 03, Brian Douglass OPTION | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r23 · c22 · span 1873099–1873106 |
| 8 | Section 03, Brian Douglass RSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r22 · c22 · span 1864372–1864379 |
| 9 | Section 03, Ralf Kuriyel OPTION | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r18 · c22 · span 1829447–1829454 |
| 10 | Section 03, Ralf Kuriyel RSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r19 · c22 · span 1838173–1838180 |
| 11 | Section 03, Jason Garland OPTION | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r8 · c22 · span 1742304–1742311 |
| 12 | Section 03, James Bylund OPTION | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r13 · c22 · span 1785943–1785950 |
| 13 | Section 03, Brian Douglass PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r25 · c22 · span 1890567–1890574 |
| 14 | Section 03, Jason Garland PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r10 · c22 · span 1759752–1759759 |
| 15 | Section 03, Ralf Kuriyel PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r20 · c22 · span 1846895–1846902 |
| 16 | Section 03, James Bylund PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r15 · c22 · span 1803391–1803398 |
| 17 | Section 03, James Bylund PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r12 · c22 · span 1777219–1777225 |
| 18 | Section 03, James Bylund RSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r14 · c22 · span 1794669–1794676 |
| 19 | Section 03, Jason Garland RSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r9 · c22 · span 1751030–1751037 |
| 20 | Section 03, Brian Douglass RSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r24 · c22 · span 1881827–1881834 |
| 21 | Section 03, Olivier Loeillot PSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r6 · c22 · span 1724824–1724833 |
| 22 | Section 03, Olivier Loeillot OPTION | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r4 · c22 · span 1707370–1707379 |
| 23 | Section 03, Olivier Loeillot RSU | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t83 · r5 · c22 · span 1716099–1716108 |
| 24 | Section 07, pay ratio | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “CEO Pay Ratio”. As printed: 82 : 1. Filing ↗machine: span 2503773–2503775 |
| 25 | Section 08, Tony J. Hunt | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 671,000. Filing ↗machine: t108 · r5 · c8 · span 2834673–2834680 |
| 26 | Section 08, Karen A. Dawes | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 355,275. Filing ↗machine: t108 · r3 · c10 · span 2826970–2826977 |
| 27 | Section 08, Glenn P. Muir | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 340,275. Filing ↗machine: t108 · r9 · c10 · span 2852312–2852319 |
| 28 | Section 08, Margaret A. Pax | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 318,803. Filing ↗machine: t108 · r10 · c10 · span 2856534–2856541 |
| 29 | Section 08, Martin Madaus | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 316,275. Filing ↗machine: r7 · c10 · span 2843872–2843879 |
| 30 | Section 08, Nicolas M. Barthelemy | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 311,747. Filing ↗machine: t108 · r2 · c10 · span 2822748–2822755 |
| 31 | Section 08, Rohin Mhatre | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 305,275. Filing ↗machine: t108 · r8 · c10 · span 2848091–2848098 |
| 32 | Section 08, Carrie Eglinton Manner | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 305,275. Filing ↗machine: t108 · r4 · c10 · span 2831199–2831206 |
| 33 | Section 08, Konstantin Konstantinov | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 300,275. Filing ↗machine: t108 · r6 · c10 · span 2839649–2839656 |
| 34 | Section 08, Olivier Loeillot | DEF 14A | 2026-04-02 | 0001193125-26-140115 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 02, Olivier Loeillot 2026-04-21 | Form 4 | 2026-04-22 | 0001193125-26-169682 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Glenn P. Muir 2026-05-07 | Form 4 | 2026-05-08 | 0001193125-26-214293 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Brian Douglass 2026-05-07 | Form 4 | 2026-05-08 | 0001193125-26-214265 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Glenn P. Muir 2026-05-07 | Form 4 | 2026-05-08 | 0001193125-26-214293 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Karen A. Dawes 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228884 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Rohin Mhatre 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228888 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Glenn P. Muir 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228891 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Glenn P. Muir 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228891 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Martin Madaus 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228896 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Manner Carrie Eglinton 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228893 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Martin Madaus 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228896 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Nicolas M. Barthelemy 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Rohin Mhatre 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228888 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Margaret A. Pax 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228886 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Margaret A. Pax 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228886 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Konstantin Konstantinov 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228897 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Nicolas M. Barthelemy 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Manner Carrie Eglinton 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228893 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Konstantin Konstantinov 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228897 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Karen A. Dawes 2026-05-14 | Form 4 | 2026-05-18 | 0001193125-26-228884 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Jason Garland 2026-06-25 | Form 4 | 2026-06-26 | 0001193125-26-285449 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Jason Garland 2026-07-16 | Form 4 | 2026-07-17 | 0001193125-26-307925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 06, 2026 vote | Form 8-K | 2026-05-15 | 0001193125-26-225380 | Item 5.07 · say-on-pay result. As reported: 96.99% (votes for as printed: 50,333,558). Filing ↗ |
| 58 | Section 06, 2025 vote | Form 8-K | 2025-05-15 | 0000950170-25-072664 | Item 5.07 · say-on-pay result. As reported: 96.55% (votes for as printed: 49,435,575). Filing ↗ |
| 59 | Section 06, 2024 vote | Form 8-K | 2024-05-17 | 0001193125-24-141217 | Item 5.07 · say-on-pay result. As reported: 94.15% (votes for as printed: 46,636,342). Filing ↗ |
| 60 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 61 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 62 | Section 09b board cost (computed) | Computed | — | computed | Cash 671,000 + equity 959,456 + all other 671,000 = 2,301,456, summed across the director compensation table rows.machine: formula: Σ = 2,301,456 |
| 63 | Halozyme Therapeutics, Inc, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 64 | Insulet Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013333 | CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087 |
| 65 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 66 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 67 | Medpace Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001668397-26-000012 | CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781 |
| 68 | Azenta, Inc., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 69 | Maravai LifeSciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 70 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 71 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 72 | Neogen Corporation, Section 10b CEO total | DEF 14A | 2025-09-12 | 0000950170-25-114381 | CEO total compensation as printed in Neogen Corporation's own proxy. As printed: 6,824,891. Filing ↗machine: r3 · c31 · span 1277142–1277151 |
| 73 | Mesa Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0000724004-26-000071 | CEO total compensation as printed in Mesa Laboratories, Inc.'s own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955 |
| 74 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 75 | Repligen Corp (subject), Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corp's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 76 | Quanterix Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 77 | Bruker Corporation, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151305 | CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. Filing ↗machine: t77 · r2 · c18 · span 987303–987312 |
| 78 | Section 10a, Mesa Laboratories, Inc. reciprocity | DEF 14A | — | 0000724004-26-000071 | Mesa Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |
| 79 | Section 10a, Insulet Corporation reciprocity | DEF 14A | — | 0001140361-26-013333 | Insulet Corporation's most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |
| 80 | Section 10a, Quanterix Corporation reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix Corporation's most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |
| 81 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation names Repligen Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Neogen Corporation reciprocity | DEF 14A | — | 0001193125-26-360742 | Neogen Corporation names Repligen Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 83 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc. names Repligen Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 84 | Section 10a, Azenta, Inc. reciprocity | DEF 14A | — | 0001140361-25-046064 | Azenta, Inc. names Repligen Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 85 | Section 10a, Bruker Corporation reciprocity | DEF 14A | — | 0001193125-26-151305 | Bruker Corporation's most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |
| 86 | Section 10a, Halozyme Therapeutics, Inc reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc's most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |
| 87 | Section 10a, Maravai LifeSciences Holdings, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeSciences Holdings, Inc. names Repligen Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 88 | Section 10a, Medpace Holdings, Inc. reciprocity | DEF 14A | — | 0001668397-26-000012 | Medpace Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |
| 89 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc. names Repligen Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 90 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation's most recent proxy was read; its disclosed peer group does not include Repligen Corp. Filing ↗ |